Background: Malignant mesothelioma (MM) is a highly aggressive, incurable asbestos-induced cancer for which treatment options are limited. Surgical resection can reduce tumour burden, but patients ultimately succumb to disease due to reoccurrence of unresectable tumour, highlighting the need for new treatment modalities. In this study we describe the use of an easily translatable heat shock (HS) treated autologous tumour lysate vaccine and discus its potential application as an adjunct therapy for treating MM. Methods: Heat shocked autologous tumour lysate (HSL) vaccine was generated from AE17sOVA mesothelioma cells and tested for its ability to act as a protective or therapeutic vaccine in a murine tumour model. Vaccine efficacy was assessed by tumour growth/survival of vaccinated mice and FACS analysis used to assess DC maturation and trafficking from vaccine site to draining lymphnodes (dLN). Results: Mice vaccinated prior to tumour challenge with HS lysate induced protection in 40% of mice and caused a significant delay in tumour progression in remaining mice. Vaccine dose-response experiments showed that HS lysate was at least a log more efficient at retarding tumour growth and promoting survival than untreated lysate. HS and untreated lysate were equally effective at maturating DCs, but HS lysate improved trafficking of vaccine-site DCs to draining lymph nodes (dLN). Direct intratumoural injection of HS lysate significantly delayed tumour progression. Conclusions: HS treatment of tumour lysate improved vaccine immunogenicity, was associated with DC maturation, increased DC trafficking to dLNs and delayed tumour growth, particularly when administered intratumourally. Heat shocking autologous tumour cells is a simple and easily translatable approach to generate an immunogenic lysate vaccine with significant prophylactic and therapeutic effects. Coupling intratumoural HS vaccines with conventional therapies such as surgery may improve patient responses for otherwise refractive tumours.
KeywordsHsp70ImmunotherapyAdjuvantLung Cancer
S. Janetzki, D. Palla, V. Rosenhauer, H. Lochs, J. J. Lewis and P. K. Srivastava, “Immunization of Cancer Patients with Autologous Cancer-Derived Heat Shock Protein gp96 Preparations: A Pilot Study,” International Journal of Cancer, Vol. 88, No. 2, 2000, pp. 232-238. doi:10.1002/1097-0215(20001015)88:2 3.0.CO;2-8
V. Mazzaferro, J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchiano, S. Andreola, R. Camerini, M. Corsi, J. J. Lewis, P. K. Srivastava and G. Parmiani, “Vaccination with Autologous Tumor-Derived Heat-Shock Protein gp96 after Liver Resection for Metastatic Colorectal Cancer,” Clinical Cancer Research, Vol. 9, No. 9, 2003, pp. 3235-3245.
H. Bendz, S. C. Ruhland, M. J. Pandya, O. Hainzl, S. Riegelsberger, C. Brauchle, M. P. Mayer, J. Buchner, R. D. Issels and E. Noessner, “Human Heat Shock Protein 70 Enhances Tumor Antigen Presentation through Complex Formation and Intracellular Antigen Delivery without Innate Immune Signaling,” Journal of Biological Chemistry, Vol. ,282 No. 43, 2007, pp. 31688-31702. doi:10.1074/jbc.M704129200
R. J. Binder, N. E. Blachere and P. K. Srivastava, “Heat Shock Protein-Chaperoned Peptides but Not Free Peptides Introduced into the Cytosol Are Presented Efficiently by Major Histocompatibility Complex I Molecules,” Journal of Biological Chemistry, Vol. 267, No. 20, 2001, pp. 17163-17171. doi:10.1074/jbc.M011547200
R. J. Binder and P. K. Srivastava, “Peptides Chaperoned by Heat-Shock Proteins Are a Necessary and Sufficient Source of Antigen in the Cross-Priming of CD8 + T Cells,” Nature Immunology, Vol. 6, No. 6, 2005, pp. 593-599. doi:10.1038/ni1201
P. K. Srivastava, “Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation,” Advance in Cancer Research, Vol. 62, 1993, pp. 153-177.
P. K. Srivastava, A. Menoret, S. Basu, R. J. Binder and K. L. McQuade, “Heat Shock Proteins Come of Age: Primitive Functions Acquire New Roles in an Adaptive World,” Immunity, Vol. 8, No. 6, 1998, pp. 657. doi:10.1016/S1074-7613(00)80570-1
B. Berwin, R. C. Reed and C. V. Nicchitta, “Virally Induced Lytic Cell Death Elicits the Release of Immunogenic GRP94/gp96,” Journal of Biological Chemistry, Vol. 276, No. 24, 2001, pp. 21083-21088. doi:10.1074/jbc.M101836200
P. Srivastava, “Interaction of Heat Shock Proteins with Peptides and Antigen Presenting Cells: Chaperoning of the Innate and Adaptive Immune Responses,” Annuls Reviews of Immunology, Vol. 20, 2002, pp. 395-425.
A. Asea, M. Rehli, E. Kabingu, J. A. Boch, O. Bare, P. E. Auron, M. A. Stevenson and S. K. Calderwood, “Novel Signal Transduction Pathway Utilized by Extracellular HSP70: Role of Toll-Like Receptor (TLR) 2 and TLR4,” Journal of Biological Chemistry, Vol. 277, No. 17, 2002, pp. 15028-15034. doi:10.1074/jbc.M200497200
R. M. Vabulas, P. Ahmad-Nejad, C. da Costa, T. Miethke, C. J. Kirschning, H. Hacker and H. Wagner, “Endocytosed HSP60s Use Toll-Like Receptor 2 (TLR2) and TLR4 to Activate the Toll/Interleukin-1 Receptor Signaling Pathway in Innate Immune Cells,” Journal of Biological Chemistry, Vol. 276, No. 33, 2001, pp. 31332-31339. doi:10.1074/jbc.M103217200
A. Asea, S. K. Kraeft, E. A. Kurt-Jones, M. A. Stevenson, L. B. Chen, R. W. Finberg, G. C. Koo and S. K. Calderwood, “HSP70 Stimulates Cytokine Production through a CD14-Dependant Pathway, Demonstrating Its Dual Role as a Chaperone and Cytokine,” Nature Medicine, Vol. 6, No. 4, 2000, pp. 435-442. doi:10.1038/74697
S. Basu, R. J. Binder, R. Suto, K. M. Anderson and P. K. Srivastava, “Necrotic but Not Apoptotic Cell Death Releases Heat Shock Proteins, Which Deliver a Partial Maturation Signal to Dendritic Cells and Activate the NFKappa B Pathway,” International Immunology, Vol. 12, No. 11, 2000, pp. 1539-1546. doi:10.1093/intimm/12.11.1539
C. Massa, C. Melani and M. P. Colombo, “Chaperon and Adjuvant Activity of hsp70: Different Natural Killer Requirement for Cross-Priming of Chaperoned and Bystander Antigens,” Cancer Research, Vol. 65, No. 17, 2005, pp. 7942-7949.
G. Multhoff, L. Mizzen, C. C. Winchester, C. M. Milner, S. Wenk, G. Eissner, H. H. Kampinga, B. Laumbacher and J. Johnson, “Heat Shock Protein 70 (Hsp70) Stimulates Proliferation and Cytolytic Activity of natural Killer Cells,” Experimental Hematology, Vol. 27, No. 11, 1999, pp. 1627-1636. doi:10.1016/S0301-472X(99)00104-6
C. Jackaman, C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. Robinson and D. J. Nelson, “IL-2 Intratumoral Immunotherapy Enhances CD8 + T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2,” Journal of Immunology, Vol. 171, No. 10, 2003, pp. 5051-5063.
K. Inaba, M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu and R. M. Steinman, “Generation of Large Numbers of Dendritic Cells from Mouse Bone Marrow Cultures Supplemented with Granulocyte/Macrophage Colony-Stimulating Factor,” Journal of Experimental Medicine, Vol. 176, No. 6, 1992, pp. 1693-1702. doi:10.1084/jem.176.6.1693
S. Henri, D. Vremec, A. Kamath, J. Waithman, S. Wil- liams, C. Benoist, K. Burnham, S. Saeland, E. Handman and K. Shortman, “The Dendritic Cell Populations of Mouse Lymph Nodes,” Journal of Immunology, Vol. 167, No. 2, 2001, pp. 741-748.
A. L. Marzo, R. A. Lake, B. W. Robinson and B. Scott, “T-cell Receptor Transgenic Analysis of Tumor-Specific CD8 and CD4 Responses in the Eradication of Solid Tumors,” Cancer Research, Vol. 59, No. 5, 1999, pp. 1071-1079.
R. S. Allan, J. Waithman, S. Bedoui, C. M. Jones, J. A. Villadangos, Y. Zhan, A. M. Lew, K. Shortman, W. R. Heath and F. R. Carbone, “Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population for Efficient CTL Priming,” Immunity, Vol. 25, No. 1, 2006, pp. 153-162. doi:10.1016/j.immuni.2006.04.017
B. W. Robinson and R. A. Lake, “Advances in Malignant Mesothelioma,” The New England Journal of Medicine, Vol. 353, No. 15, 2005, pp. 1591-1603. doi:10.1056/NEJMra050152
C. Jandus, D. Speiser and P. Romero, “Recent Advances and Hurdles in Melanoma Immunotherapy,” Pigment Cell & Melanoma Research, Vol. 22, No. 6, 2009, pp. 711-7 23.
J. Rotow, S. R. Gameiro, R. A. Madan, J. L. Gulley, J. Schlom and J. W. Hodge, “Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer,” Clinical and Translational Science, Vol. 3, No. 3, 2010 pp. 116-122. doi:10.1111/j.1752-8062.2010.00186.x
T. D. de Gruijl, A. J. van den Eertwegh, H. M. Pinedo and R. J. Scheper, “Whole-Cell Cancer Vaccination: From Autologous to Allogeneic Tumor- and Dendritic Cell-Based Vaccines,” Cancer Immunology, Immunotherapy, Vol. 57, No. 10, 2008, pp. 1569-1577. doi:10.1007/s00262-008-0536-z
P. K. Srivastava, M. K. Callahan and M. M. Mauri, “Treating Human Cancers with Heat Shock Protein-Peptide Complexes: The Road Ahead,” Expert Opinion on Biological Therapy, Vol. 9, No. 2, 2009, pp. 179-186. doi:10.1517/14712590802633918
J. Gong, Y. Zhang, J. Durfee, D. Weng, C. Liu, S. Koido, B. Song, V. Apostolopoulos and S. K. Calderwood, “A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use,” Journal of Immunology, Vol. 184, No. 1, 2010, pp. 488-496. doi:10.4049/jimmunol.0902255
A. Powell, J. Creaney, S. Broomfield, I. Van Bruggen and B. Robinson, “Recombinant GM-CSF plus Autologous Tumor Cells as a Vaccine for Patients with Mesothelioma,” Lung Cancer, Vol. 52, No. 2, 2006, pp. 189-197. doi:10.1016/j.lungcan.2006.01.007
C. Jackaman, A. M. Lew, Y. Zhan, J. E. Allan, B. Koloska, P. T. Graham, B. W. Robinson and D. J. Nelson, “Deliberately Provoking Local Inflammation Drives Tumors to Become Their Own Protective Vaccine Site,” International Immunology, Vol. 20, No. 11, 2008, pp. 1467-1479.
E. Liapi and J. F. Geschwind, “Transcatheter and Ablative Therapeutic Approaches for Solid Malignancies,” Journal of Clinical Oncology, Vol. 25, No. 8, 2007, pp. 978-986. doi:10.1200/JCO.2006.09.8657
R. A. McTaggart and D. E. Dupuy, “Thermal Ablation of Lung Tumors,” Techniques in Vascular & Interventional Radiology, Vol. 10, No. 2, 2007, pp. 102-113. doi:10.1053/j.tvir.2007.09.004
B. B. Pua, R. H. Thornton and S. B. Solomon, “Ablation of Pulmonary Malignancy: Current Status,” Journal of Vascular and Interventional Radiology, Vol. 21, Supplement 8, 2010, pp. S223-S232.
W. L. Yang, D. G. Nair, R. Makizumi, G. Gallos, X. Ye, R. R. Sharma and T. S. Ravikumar, “Heat Shock Protein 70 Is Induced in Mouse Human Colon Tumor Xenografts after Sublethal Radiofrequency Ablation,” Annuals of Surgical Oncology, Vol. 11, No. 4, 2004, pp. 399-406.
Q. Liu, B. Zhai, W. Yang, L. X. Yu, W. Dong, Y. Q. He, L. Chen, L. Tang, Y. Lin, D. D. Huang, H. P. Wu, M. C. Wu, H. X. Yan and H. Y. Wang, “Abrogation of Local Cancer Recurrence after Radiofrequency Ablation by Dendritic Cell-Based Hyperthermic Tumor Vaccine,” Molecular Therapy, Vol. 17, No. 12, 2009, pp. 2049-2057. doi:10.1038/mt.2009.221